<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04913831</url>
  </required_header>
  <id_info>
    <org_study_id>4-2021-0085</org_study_id>
    <nct_id>NCT04913831</nct_id>
  </id_info>
  <brief_title>Effects of Cerebrolysin on Level of Consciousness and Brain Metabolism in Disorder of Consciousness After Stroke: Single Center Randomized Controlled Study</brief_title>
  <official_title>Effects of Cerebrolysin on Level of Consciousness and Brain Metabolism in Disorder of Consciousness After Stroke: Single Center Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to determine the effect of stroke on post-stroke level of&#xD;
      consciousness through a double-blind, placebo-controlled, randomized study design. And Brain&#xD;
      18F-FDG PET was used to reveal the mechanism of recovery after cerebrolysin administration.&#xD;
&#xD;
      Thirty patients with chronic stroke patients with minimal consciousness (MCS) or vegetative&#xD;
      human (VS) level of consciousness disorder in the revised coma recovery scale were enrolled.&#xD;
      Thirty patients were randomly divided into a Cerebrolysin group and a placebo group.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CRS-R (JFK Coma recovery scale-revised)</measure>
    <time_frame>up to 11 weeks</time_frame>
    <description>It is a test that analyzes a total of six functions of hearing, vision, movement, speech, communication, and arousal by item to determine the improvement in the level of consciousness of patients with decreased consciousness. These items are scored to determine whether they are in a minimally conscious state (MCS).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Cerebrolysin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cerebrolysin</intervention_name>
    <description>Cerebrolysin 20ml + physiological saline 80ml, 8-35 days, once/day, intravenous administration</description>
    <arm_group_label>Cerebrolysin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>physiological saline 100ml, 8-35 days, once/day, intravenous administration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ischemic or hemorrhagic stroke patients&#xD;
&#xD;
          -  Stroke with CT or MRI diagnosis&#xD;
&#xD;
          -  Chronic patients with more than 3 months of stroke onset&#xD;
&#xD;
          -  Patients with vegetative status or minimal consciousness (Coma Recovery Scale&#xD;
             -revised: CRS-R)&#xD;
&#xD;
          -  Age: 19 to 90 years old&#xD;
&#xD;
          -  A person who voluntarily consents to the clinical trial in writing by the principal or&#xD;
             legal representative&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  In case of contraindications, including allergies to cerebrolysin&#xD;
&#xD;
          -  Patients with contraindications to PET&#xD;
&#xD;
          -  Progressive or unstable stroke&#xD;
&#xD;
          -  In case of accompanying serious neurogenic disease&#xD;
&#xD;
          -  Major depressive disorder, schizophrenia, bipolar disorder, dementia, and other&#xD;
             serious psychiatric diseases.&#xD;
&#xD;
          -  History of alcohol or other drug addiction within 3 years of onset&#xD;
&#xD;
          -  In case of accompanying serious liver, kidney, heart, or respiratory disease&#xD;
&#xD;
          -  If you have the following medical abnormalities (Total serum bilirubin&gt; 4 mg/dL,&#xD;
             alkaline phosphatase&gt; 250 U/L, SGOT/AST&gt; 150 U/L, SGPT/ALT&gt; 150 U/L, or creatinine) &gt;&#xD;
             3.5 mg/dL)&#xD;
&#xD;
          -  In case of having a medical disease that is less than 1 year old&#xD;
&#xD;
          -  During pregnancy or lactation&#xD;
&#xD;
          -  Participating in other therapeutic research&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deog Young Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department and Research Institute of Rehabilitation Medicine, Yonsei University College of Medicine, Seoul, Yonsei University College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Deog Young Kim</last_name>
    <phone>82-2-2228-3714</phone>
    <email>KIMDY@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yonsei University Health System, Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deog Young Kim</last_name>
      <phone>82-2-2228-3714</phone>
      <email>KIMDY@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 25, 2021</study_first_submitted>
  <study_first_submitted_qc>May 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2021</study_first_posted>
  <last_update_submitted>May 26, 2021</last_update_submitted>
  <last_update_submitted_qc>May 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Consciousness Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebrolysin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

